Clinical evaluation of chronic nephrotoxicity of long-term cyclosporine A treatment in adult patients with steroid-dependent nephrotic syndrome

Nephrology

Volumn 16, Issue 3, 2011, Pages 319-325

  Okada, Tomonari ^a   Matsumoto, Hiroshi ^a   Nagaoka, Yume ^a   Tomaru, Ryo ^a   Iwasawa, Hideaki ^a   Wada, Toshikazu ^a   Nakao, Toshiyuki ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

cyclosporine; hypomagnesemia; nephrotic syndrome; nephrotoxicity

Indexed keywords

ALPHA 1 MICROGLOBULIN; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; MAGNESIUM; METHYLPREDNISOLONE; MIZORIBINE;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHRONIC TOXICITY; CLINICAL ARTICLE; CORRELATION ANALYSIS; CORTICOSTEROID THERAPY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LONG TERM CARE; LOW DRUG DOSE; MAGNESIUM BLOOD LEVEL; MALE; NEPHROTIC SYNDROME; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RELAPSE; REMISSION; TREATMENT DURATION;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD PRESSURE; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; JAPAN; KIDNEY; MAGNESIUM; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951980106     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2010.01425.x     Document Type: Article

References (30)

1. Fujimoto S, Yamamoto Y, Hisanaga S, Morita S, Eto T, Tanaka K,. Minimal change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse. Am. J. Kidney Dis. 1991; 17: 687-92.
2. Mak SK, Short CD, Mallick NP,. Long-term outcome of adult-onset minimal change nephropathy. Nephrol. Dial. Tranplant. 1996; 11: 2192-201. (Pubitemid 26385914)
3. Nakayama M, Katafuchi R, Yanase T, Ikeda K, Tanaka H, Fujimi S,. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am. J. Kidney Dis. 2002; 39: 503-12. (Pubitemid 34194626)
4. Tse KC, Lam MF, Yip PS, et al. Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses. Nephrol. Dial. Transplant. 2003; 18: 1316-20.
5. Waldman M, Crew RJ, Valeri A, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin. J. Am. Soc. Nephrol. 2007; 2: 445-53.
6. Matsumoto H, Nakao T, Okada T, et al. Initial remission-inducing effect of very low-dose cyclosporine monotherapy for minimal-change nephrotic syndrome in Japanese adults. Clin. Nephrol. 2001; 55: 143-8. (Pubitemid 32151002)
7. Matsumoto H, Nakao T, Okada T, et al. Favorable outcome of low-dose cyclosporine after methylpredonisolone in Japanese adult minimal-change nephrotic syndrome. Intern. Med. 2004; 43: 668-73. (Pubitemid 39264164)
8. Eguchi A, Takei T, Yoshida T, Tsuchiya K, Nitta K,. Combined cyclosporine and predonisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome. Nephrol. Dial. Transplant. 2010; 25: 124-9.
9. Cattran DC, Alexopoulous E, Heering P, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int. 2007; 72: 1429-47. (Pubitemid 350197945)
10. Lindelöw B, Bergh CH, Herlitz H, Waagstein F, for the Heart and Lung Transplantation Group. Predictors and evolution of renal function during 9 years following heart transplantation. J. Am. Soc. Nephrol. 2000; 11: 951-7. (Pubitemid 30241731)
11. Nankivell B, Richard J, Borrows R, et al. The natural history of chronic allograft nephropathy. N. Engl. J. Med. 2003; 349: 2326-33. (Pubitemid 37509740)
12. Hamour IM, Omar F, Lyster HS, Palmer A, Banner NR,. Chronic kidney disease after heart transplantation. Nephrol. Dial. Transplant. 2009; 24: 1655-62.
13. Iijima K, Hamahira K, Tanaka R, et al. Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int. 2002; 61: 1801-5. (Pubitemid 34437934)
14. Fujinga S, Kaneko K, Muto T, Ohmoto Y, Murakami H, Yamashiro Y,. Independent risk factors for cyclosporine induced nephropathy in children with nephrotic syndrome. Arch. Dis. Child. 2006; 91: 666-70. (Pubitemid 44197108)
15. Kranz B, Vester U, Büscher R, Wingen AM, Hoyer PF,. Cyclosporine induced nephrotoxicity in children with minimal change nephrotic syndrome: long-term treatment up to 10 years. Pediatr. Nephrol. 2008; 23: 581-6.
16. Kengrne-Wafo S, Massella L, Diomedi-Camassei F, et al. Risk factors for cyclosporine A nephrotoxicity in children with steroid-dependent nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 2009; 4: 1409-16.
17. Holzmacher R, Kendziorski C, Hofman RM, Jaffery J, Becker B, Djamali A,. Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity. Nephrol. Dial. Transplant. 2005; 20: 1456-62. (Pubitemid 41430621)
18. Sabbagh F, El Tawil Z, Lecerf F, et al. Impact of cyclosporine A on magnesium homeostasis: clinical observation in lung transplant recipients and experimental study in mice. Transplantation 2008; 86: 436-44.
19. Lima Mde L, Cruz T, Rodrigues LE, et al. Serum and intracellular magnesium deficiency in patients with metabolic syndrome-evidences for its relation to insulin resistance. Diabetes Res. Clin. Pract. 2009; 82: 257-62.
20. Reffelmann T, Dörr M, Ittermann T, et al. Low serum magnesium concentrations predict increase in left ventricular mass over 5 years independently of common cardiovascular risk factors. Atherosclerosis 2010; 213: 563-9.
21. Franz S, Regeniter A, Hopfer H, Mihatsch M, Dickernmann M,. Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial. Am. J. Kidney Dis. 2009; 55: 335-43.
22. Bizzi C, Petrini C, Rizza V, et al. Urinary excretion of IgG and alpha(1)-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy. Am. J. Kidney Dis. 2001; 38: 406-8.
23. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 2009; 53: 982-92.
24. Meyrier A, Noël LH, Auriche P, Callard P, and the Collaborative Group of the Société de Nephrology, with the technical assistance of Bronner D. Long-term renal tolerance of cyclosporine A treatment in adult idiopathic nephrotic syndrome. Kidney Int. 1994; 45: 1446-56. (Pubitemid 24135033)
25. Robert M, Wong GW, Wright JM,. Effect of cyclosporine on blood pressure. Cochrane Database Syst. Rev. 2010; 1: CD007893, 1- 47.
26. Chang CT, Hung CC, Tian YC, Yang CW, Wu MS,. Cyclosporin reduces paracellin-1 expression and magnesium transport in thick ascending limb cells. Nephrol. Dial. Transplant. 2007; 22: 1033-40.
27. Alexander RT, Hoenderop JG, Bindels RJ,. Molecular determinants of magnesium homeostasis: insights from human disease. J. Am. Soc. Nephrol. 2008; 19: 1451-8.
28. Ikari A, Okude C, Sawada H, Takahashi T, Sugatani J, Miwa H,. Down-regulation of TRPM6-mediated magnesium influx by cyclosporine A. Naunyn Schmiedebergs Arch. Pharmacol. 2008; 377: 333-43.
29. Naesens M, Kuypers DRJ, Sarwal M,. Calcineurin inhibitor nephrotoxicity. Clin. J. Am. Soc. Nephrol. 2009; 4: 481-508.
30. Porrini E, Delgdo P, Alvarez A, et al. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation. Nephrol. Dial. Transplant. 2008; 23: 1436-41. (Pubitemid 351767488)